DFTX Mind Medicine (MindMed) Inc. Insider Trading

CLO Mark Sullivan sells 13,008 shares of DFTX at $45.03 under pre-arranged 10b5-1 plan; retains 320,571 shares post-sale

Mark Sullivan (Chief Legal Officer) sold 13,008 shares at $45.03 on 2026-06-25 under a 10b5-1 trading plan adopted on 2024-03-14, generating $585,750.24 in proceeds. This is a scheduled, non-discretionary transaction rather than a discretionary sale decision. Sullivan retained 320,571 shares post-transaction, representing a -3.9% reduction in his holdings. The sale occurred as the stock trades at $44.95 (current price), near its 52-week high of $47.01, though the company reported a negative net income of $-77,098,000.00 over its most recent full fiscal year.

CEO Robert Barrow sold 29,208 shares of DFTX at $45.03 under 10b5-1 plan; remains 1.10M shares post-sale

Robert Barrow, Chief Executive Officer, sold 29,208 shares on 2026-06-25 at $45.03 under a pre-arranged 10b5-1 trading plan adopted on 2022-06-15, reducing his holdings from 1.13M to 1.10M shares. The sale is scheduled, not discretionary. Definium Therapeutics is currently unprofitable with net income of $-77,098,000.00 over its most recent full fiscal year, with a $4.9B market cap. The stock is trading at $44.95, down 4.4% from its 52-week high of $47.01, though it has gained 91.1% over the past 30 days and 151.4% over 90 days. The pre-arranged nature of this transaction removes timing as an interpretable signal.

Director GRYSKA DAVID W bought 2,500 shares at $7.17; stock now at $7.11, up 19.6% over 90 days from unprofitable company.

GRYSKA DAVID W purchased 2,500 shares on 2024-12-05 at $7.17, increasing his holdings from 17.4K to 19.9K shares—a 14.4% increase in his position. The company is unprofitable with net income of $-13.7M, and the stock trades 39.5% below its 52-week high of $11.75. His prior buy at this ticker on 2024-08-23 generated a 90-day return of +18.6%, a well-timed entry. This current purchase comes after the stock has rallied 19.6% over the last 90 days and 15.6% over the last 30 days, suggesting he is buying into positive momentum rather than a depressed or recovery scenario. The timing and magnitude of this open-market purchase merit monitoring given the company's unprofitable status and the stock's extended position off its recent lows.

Director David W Gryska bought 3,500 shares of MNMD at $5.98 on 2024-08-23; stock down 34.9% in 30 days and -47.9% from 52-week high.

Director David W Gryska purchased 3,500 shares at $5.98, increasing his holdings by 25.3% to 17,351 shares post-transaction. The purchase occurs during a period of significant price deterioration: the stock has declined 34.9% over the past 30 days and 47.9% from its 52-week high of $11.75. Mind Medicine is unprofitable with net income of $-5.9M in its most recent full fiscal year, a fundamental weakness that undercuts the significance of the open-market buy signal. The combination of sustained downward price momentum, unprofitable operations, and a director's mid-downturn accumulation suggests monitoring rather than conviction, as the broader context lacks earnings stability to support a bullish interpretation of the insider purchase.

MindMed CEO Barrow purchased 1,000 shares in 2 transactions for $6,215.00 total amid -47.5% drawdown from 52-week high

Robert Barrow, Chief Executive Officer of MindMed, executed two separate share purchases totaling 1,000 shares for $6,215.00 on August 19–20, 2024. These purchases occurred at a blended average price of $6.22, while the current stock price of $6.17 is 47.5% below the 52-week high of $11.75 and has declined 22.2% over the prior 30 days and 26.6% over 90 days. The company reported a full-year net loss of $5.9M. While insider purchasing during a significant drawdown warrants attention, the position size—adding just 1,000 shares to an existing 564.5K share position—represents a modest 0.2% increment to his holdings, and the timing during broad-based weakness in the stock offers limited clarity on forward conviction absent additional context.